Abbott is shortly to provide a digital health app that can be used to track and report patient perceived pain relief and overall well-being associated with spinal cord stimulation (SCS) or dorsal root ganglion (DRG) therapy.
NeuroSphere ™ myPath ™ enables patients to record pain results during the device test period before a neuromodulation device is permanently implanted. Patients can share the information gathered in the app with healthcare providers for a comprehensive assessment of SCS or DRG therapy. The app also includes access to educational resources and connection to Abbott support.
The digital health app will be compatible with Abbott’s Proclaim XR SCS system for patients with chronic trunk and limb pain and the Proclaim DRG neurostimulation system for patients with chronic lower limb pain caused by complex regional pain syndrome or cause causalgia.
“The introduction of NeuroSphere myPath is another example of Abbott’s leadership in providing remote ways to connect doctors and patients,” said Keith Boettiger, vice president of Neuromodulation, Abbott. “Patients can see information on their phone that is normally only available in a doctor’s office. This enables patients to share their journey with their doctors.”
NeuroSphere myPath will be available in the Apple App Store in the coming weeks and is expected to be available on Android devices in the second quarter of 2021.
Visit abbott.com for more information.
Abbott launches NeuroSphere ™ myPath ™ digital health app, which enables physicians to track and report pain relief in patients with chronic pain prior to device implantation. [press release]. Abbott Park, IL: Abbott; January 14, 2021.
This article originally appeared on Clinical Pain Advisor
Chronic Pain Pain Pain Treatments